Format

Send to

Choose Destination
Expert Rev Vaccines. 2014 Feb;13(2):299-312. doi: 10.1586/14760584.2014.863715. Epub 2013 Nov 26.

Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Author information

1
Department of Clinical Oncology, Tohoku University, Japan.

Abstract

CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding the mechanism of action of CpG ODN and provide an overview of human clinical trial results using CpG ODN to improve the vaccines for cancer, allergy and infectious disease.

PMID:
24308579
PMCID:
PMC6335645
DOI:
10.1586/14760584.2014.863715
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center